Association of eNOS and MCP-1 Genetic Variants with Type 2 Diabetes and Diabetic Nephropathy Susceptibility: A Case–Control and Meta-Analysis Study

Raina, Priyanka; Sikka, Ruhi; Gupta, Himanshu; Matharoo, Kawaljit; Bali, Surinder K.; Singh, Virinder; Bhanwer, A.J.S.

doi:10.1007/s10528-021-10041-2

Cited by 18 publications

(9 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic polymorphisms in the eNOS gene are shown to affect their activity and may also promote CKD progression in diabetic and hypertension patients [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of NOS3 (rs 2070744) and SOD2Val16Ala (rs4880) gene polymorphisms with increased risk of ESRD among Egyptian patients

Elsaid

eid

Said

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Chronic kidney Failure (CKD), particularly End-Stage Renal Disease (ESRD), may be serious ill-health related to a high death rate. Uremic syndrome leads to increased oxidative stress, inflammation, and dyslipidemia. Our study aimed at identifying the association of NOS3 (rs 2070744) and SOD2 Val16Ala (rs4880) gene polymorphisms within ESRD Egyptian patients. Methods This work was conducted on 100 ESRD and 16 CKD Egyptian patients who were compared to 100 healthy controls. DNA was genotyped for these variants using the (T-ARMS-PCR) technique. Results ESRD patients showed a significant association of the genotype of NOS3 gene polymorphism compared with healthy controls (P = 0.032). In the contrast, the present study revealed that no statistically significant differences were found among the CKD, ESRD, and control groups as regards the SOD2 genotypes (P = 0.064). Conclusions Our findings indicated a significant association between NOS3 (rs 2070744) gene polymorphism and increased risk of ESRD and CKD among Egyptian patients.

show abstract

“…Genetic polymorphisms in the eNOS gene are shown to affect their activity and may also promote CKD progression in diabetic and hypertension patients [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…The functional effect of these variants is to reduce the expression of mRNA or change the function of eNOS, resulting in a reduction in NO production. Genetic variations in the eNOS gene have an essential role in the development of renal disease [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Association of NOS3 (rs 2070744) and SOD2Val16Ala (rs4880) gene polymorphisms with increased risk of ESRD among Egyptian patients

Elsaid

eid

Said

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

show abstract

“… 21 The beneficial effect of NO is partially mediated by inhibiting the expression of MCP-1 (monocyte chemoattractant protein-1). 22 Thus, regulation of endothelial integrity and function is necessary for maintaining vascular homeostasis and for preventing the development of atherosclerosis.…”

Section: Cells Involved In Atherosclerosismentioning

confidence: 99%

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Kong

Cui

Huang

et al. 2022

Sig Transduct Target Ther

218

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors. Genome-wide association combined with clonal lineage tracing and clinical trials have demonstrated that innate and adaptive immune responses can promote or quell atherosclerosis. Several signaling pathways, that are associated with the inflammatory response, have been implicated within atherosclerosis such as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt signaling pathways, which are of importance for atherosclerosis development and regression. Targeting inflammatory pathways, especially the NLRP3 inflammasome pathway and its regulated inflammatory cytokine interleukin-1β, could represent an attractive new route for the treatment of atherosclerotic diseases. Herein, we summarize the knowledge on cellular participants and key inflammatory signaling pathways in atherosclerosis, and discuss the preclinical studies targeting these key pathways for atherosclerosis, the clinical trials that are going to target some of these processes, and the effects of quelling inflammation and atherosclerosis in the clinic.

show abstract

“…Monocyte chemoattractant protein‐1 (MCP‐1/CCL2) is a ligand of C‐C motif chemokine receptor 2 (CCR‐2) and one of the most known and best studied chemokines so far 6 . Cell culture experiments and genetic studies augmented our understanding on the molecular mechanisms of its action 7,8 . In the clinical setting, MCP‐1 has been consistently found to contribute to the pathogenesis of nearly all stages and all phenotypes of chronic and diabetic kidney disease 9–12 .…”

Section: Introductionmentioning

confidence: 99%

“…6 Cell culture experiments and genetic studies augmented our understanding on the molecular mechanisms of its action. 7,8 In the clinical setting, MCP-1 has been consistently found to contribute to the pathogenesis of nearly all stages and all phenotypes of chronic and diabetic kidney disease. [9][10][11][12] Recent studies investigating novel molecules with inhibitory properties on the MCP-1/MCP-1 (CCL2/CCR2) signalling axis have offered new insights and renewed the interest on this chemokine.…”

Section: Introductionmentioning

confidence: 99%

Monocyte chemoattractant protein‐1 predicts the development of diabetic nephropathy

Scurt

Menne

Brandt

et al. 2021

Diabetes Metabolism Res

View full text Add to dashboard Cite

Aim Diabetic nephropathy (DN) is a devastating complication of diabetes mellitus (DM). Therefore, screening strategies in order to prevent its development and/or retard its progression are of paramount importance. We investigated if monocyte chemoattractant protein‐1 (MCP‐1) was associated with new onset microalbuminuria‐the earliest sign of the albuminuric phenotype of DN‐ in patients with type 2 DM and normoalbuminuria. Methods We measured MCP‐1 in serum and urine samples from patients of the Randomized Olmesartan And Diabetes Microalbuminuria Prevention (ROADMAP) study and its Observational Follow‐up (OFU) cohort. A case control design was used with inclusion of 172 patients who developed microalbuminuria (MA) and of 188 well matched controls who remained normoalbuminuric. Results The median duration of follow‐up for the ROADMAP cohorts was 6.5 years, whereas the mean time until occurrence of MA was 53.2 months. In the multivariate analysis, serum and urine MCP‐1 remained significant predictors of new onset MA. The risk for MA increased continuously with increasing serum and urine MCP‐1 levels but reached statistical significance only in the highest quartiles. The risk associations were stronger with serum MCP‐1. Conclusions MCP‐1 is a marker and possibly a mediator of early diabetic nephropathy. Further prospective studies are necessary to test whether diabetic patients with elevated MCP‐1 levels would benefit from specific therapeutic interventions.

show abstract

Association of eNOS and MCP-1 Genetic Variants with Type 2 Diabetes and Diabetic Nephropathy Susceptibility: A Case–Control and Meta-Analysis Study

Cited by 18 publications

References 96 publications

Association of NOS3 (rs 2070744) and SOD2Val16Ala (rs4880) gene polymorphisms with increased risk of ESRD among Egyptian patients

Association of NOS3 (rs 2070744) and SOD2Val16Ala (rs4880) gene polymorphisms with increased risk of ESRD among Egyptian patients

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Monocyte chemoattractant protein‐1 predicts the development of diabetic nephropathy

Contact Info

Product

Resources

About